PHOENIX — Arizona is suing a major drug maker, accusing it of gaming the system by simply renaming an asthma drug to increase ...

In a report released on February 5, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with ...

Arizona Attorney General Kris Mayes announced Thursday her office was suing a pharmaceutical company for alleged "deceptive" ...

The state’s top lawyer accused a British multinational drug company of “deceptive and unfair practices” that endangered lives and exploited American taxpayers.

GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...

Soldiers from the U.S. Army 10th Mountain Division, a light infantry division based at Fort Drum, N.Y., are being deployed to ...

American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...

CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...

Type 2 diabetes is a chronic health condition characterized by high blood glucose (sugar) levels. It is known to cause inflammation throughout the body, affecting several body systems. Many major ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...